Repligen Corp (NASDAQ:RGEN)

Getting contracts with strong manufactures is the key to growth and they are getting that.

These medical corporations tend to have spurts of large growth with long periods of notable decline. Just as Genetic Technologies as been fluctuating over the past year (a range from ~$2.50 - ~$10.00), this company follows a very similar trend. It will have spurts when it has a break through but overall it will underplay the market.

There is money in drugs

Oversold on bad news.

Get ready, this one's due. The phase 3 trial of their pancreatic secretin analogue has Fast Track and Orphan status and will be vital in diagnosing pancreatic disease with MRI. I'm thinking this technology will give Repligen a big boost in early 2011. MRI is the imaging modality of the future as it becomes more accessible and affordable, and this product will prove very useful as that occurs.

Pancreatic imaging, fools!

Good growth and earnings.

Insider purchase at higher price

way oversold!

I like the numbers for this one. It'll be a good year for biotech!

Just an idea from reading CAPS.

Repligen enjoys strong, conservative management, a large cash hoard, a significant royalty stream and an interesting pipeline. They could grow by acquisition or be acquired themselves, but they should grow nicely over the next few years.

Aug - Dec 2008 stock price has increased. Debt is not public. Obama will look to help specialty pharmaceuticals. PE tends to be high for sector.

This bio-pharmaceutical company is a bit of a gamble on my part. They've traded "in a range" for years - but it looks like they are on the brink of breaking out. Time will tell.

Giving into peer pressure

Repligen is one of the best sleeper stocks on the market. When their novel histone deacetylase (HDAC) inhibitor is shown to improved Huntinton's disease symptoms,in human trial, the stock price will double. It takes two to 5 years for human testing to be complete. Transgenic mouse modeling is complete. Keep an eye on this one.

Here is one that is a great value stock, low risk with potential of high return. Company is very well ran with great R&D. Earnings are beating analyst estimates, and right now most analysts are rating it a strong buy. Could easily be at $10 in six months, and has great potential for continual growth. PE is great, earnings are great, there is very little negative I can find to say rigth now. If you are looking for a value stock with lots of potential, RGEN is at a great price right now.

Buy back.

Undervalued. Good Fundamentals.

This stock was picked by TMFOrangeblood for the 2008 Stockpicking Contest.